CL2016002918A1 - Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo. - Google Patents

Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo.

Info

Publication number
CL2016002918A1
CL2016002918A1 CL2016002918A CL2016002918A CL2016002918A1 CL 2016002918 A1 CL2016002918 A1 CL 2016002918A1 CL 2016002918 A CL2016002918 A CL 2016002918A CL 2016002918 A CL2016002918 A CL 2016002918A CL 2016002918 A1 CL2016002918 A1 CL 2016002918A1
Authority
CL
Chile
Prior art keywords
quinazoline
methylsulfonyl
hydroxy
methyl
butanamide
Prior art date
Application number
CL2016002918A
Other languages
English (en)
Inventor
Azely Mirre
Jean-Phillippe Surivet
Gaëlle Chapoux
Jean-Christophe Gauvin
Original Assignee
Idorsia Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idorsia Pharmaceuticals Ltd filed Critical Idorsia Pharmaceuticals Ltd
Publication of CL2016002918A1 publication Critical patent/CL2016002918A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Compuestos derivados de compuestos derivados quinazolina-4(3H)-ona-N-hidroxi-2-metil-2-metilsulfonil-butanamida con actividad antibacteriana Gram negativo
CL2016002918A 2014-05-16 2016-11-16 Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo. CL2016002918A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14168718 2014-05-16

Publications (1)

Publication Number Publication Date
CL2016002918A1 true CL2016002918A1 (es) 2017-04-07

Family

ID=50731968

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2016002918A CL2016002918A1 (es) 2014-05-16 2016-11-16 Compuestos derivados de quinazolina-4(3h)-ona-n-hidroxi-2-metil-2-metilsulfonil-butanamida; composicion farmaceutica; actividad antibacteriana gram-negativo.

Country Status (19)

Country Link
US (1) US9796686B2 (es)
EP (1) EP3143007B1 (es)
JP (1) JP2017515906A (es)
KR (1) KR20170005105A (es)
CN (1) CN106458931A (es)
AR (1) AR100428A1 (es)
AU (1) AU2015261540A1 (es)
BR (1) BR112016026787A8 (es)
CA (1) CA2948077A1 (es)
CL (1) CL2016002918A1 (es)
EA (1) EA201692305A1 (es)
ES (1) ES2687040T3 (es)
IL (1) IL248922A0 (es)
MX (1) MX2016014989A (es)
PH (1) PH12016502253A1 (es)
SG (1) SG11201609286VA (es)
TW (1) TW201625559A (es)
WO (1) WO2015173329A1 (es)
ZA (1) ZA201608680B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
JP6407288B2 (ja) 2013-12-19 2018-10-17 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona
AR105646A1 (es) * 2015-08-11 2017-10-25 Actelion Pharmaceuticals Ltd Agentes antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituida
AR105839A1 (es) * 2015-08-28 2017-11-15 Actelion Pharmaceuticals Ltd Derivados antibacterianos pirrolidin-2-ona anulares
AR105889A1 (es) 2015-09-03 2017-11-22 Actelion Pharmaceuticals Ltd Compuestos antibacterianos 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona sustituidos
RU2018124788A (ru) * 2015-12-08 2020-01-15 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Замещенные бензазиноны в качестве антибактериальных соединений
US20190142811A1 (en) 2016-04-01 2019-05-16 Zeno Royalties & Milestones, LLC Estrogen receptor modulators
WO2018062924A1 (en) * 2016-09-28 2018-04-05 Dong-A St Co., Ltd. Tetrahydropyridine derivatives and their use as antibacterial agents
EP3993787A4 (en) 2019-08-06 2023-07-12 Recurium IP Holdings, LLC Estrogen receptor modulators for treating mutants

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20022626B (en) 1997-02-27 2002-02-25 American Cyanamid Company Us N-Hydroxy-2-(Alkyl, Aryl, or Heteroaryl Sulfanyl, Sulfinil or Sulfonyl)-3-Substituted Alkyl, Aryl or Heteroarylamides as Matrix Metalloproteinase Inhibitors
TWI343377B (en) 2002-03-13 2011-06-11 Array Biopharma Inc N3 alkylated benzimidazole derivatives as mek inhibitors
CA2934114A1 (en) * 2007-06-12 2008-12-18 Achaogen, Inc. Antibacterial agents
JP5455913B2 (ja) 2008-08-27 2014-03-26 大正製薬株式会社 ナフチリジン−ｎ−オキシドを有する新規ヒドロキサム酸誘導体
WO2010037210A1 (en) 2008-10-03 2010-04-08 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
DE102008044132A1 (de) 2008-11-27 2010-06-02 BSH Bosch und Siemens Hausgeräte GmbH Kältegerät mit zweiseitig anschlagbarer Tür
EP2432468A2 (en) 2009-05-20 2012-03-28 Ardea Biosciences, Inc. Methods of modulating uric acid levels
CA2774250C (en) 2009-10-13 2013-12-17 Pfizer Inc. C-linked hydroxamic acid derivatives useful as antibacterial agents
PL2512474T3 (pl) 2009-12-16 2015-03-31 Pfizer N-przyłączone pochodne kwasu hydroksamowego użyteczne jako środki przeciwbakteryjne
WO2012054332A1 (en) 2010-10-18 2012-04-26 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
AR083760A1 (es) 2010-11-10 2013-03-20 Achaogen Inc Agentes antibacterianos y composiciones farmaceuticas
US8853213B2 (en) 2011-01-03 2014-10-07 Hanmi Pharm. Co., Ltd Bicyclic compound for modulating G protein-coupled receptors
GEP20156370B (en) * 2011-03-07 2015-09-25 Pfizer Fluoro-pyridinone derivatives useful as antibacterial agents
EP2694481B1 (en) 2011-04-08 2015-12-30 Pfizer Inc Imidazole, pyrazole, and triazole derivatives useful as antibacterial agents
EP2694488B1 (en) 2011-04-08 2014-11-12 Pfizer Inc Isoxazole derivatives useful as antibacterial agents
WO2012170845A2 (en) 2011-06-08 2012-12-13 Heffernan Michele L R Metabotropic glutamate receptor 5 modulators and methods of use thereof
WO2013170030A1 (en) 2012-05-09 2013-11-14 Achaogen, Inc. Antibacterial agents
EP2847168A1 (en) * 2012-05-10 2015-03-18 Achaogen, Inc. Antibacterial agents
US10647664B2 (en) 2013-08-16 2020-05-12 Duke University Substituted hydroxamic acid compounds
AR097617A1 (es) 2013-09-13 2016-04-06 Actelion Pharmaceuticals Ltd Derivados antibacterianos del 2h-indazol
JP6407288B2 (ja) 2013-12-19 2018-10-17 イドーシア ファーマシューティカルズ リミテッドＩｄｏｒｓｉａ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ 抗菌性１ｈ−インダゾール及び１ｈ−インドール誘導体
AR099612A1 (es) 2014-03-04 2016-08-03 Actelion Pharmaceuticals Ltd Derivados antibacterianos de 1,2-dihidro-3h-pirrolo[1,2-c]imidazol-3-ona

Also Published As

Publication number Publication date
US20170081292A1 (en) 2017-03-23
BR112016026787A8 (pt) 2017-12-26
EP3143007B1 (en) 2018-07-11
EA201692305A1 (ru) 2017-05-31
CA2948077A1 (en) 2015-11-19
JP2017515906A (ja) 2017-06-15
WO2015173329A1 (en) 2015-11-19
AR100428A1 (es) 2016-10-05
ZA201608680B (en) 2018-11-28
ES2687040T3 (es) 2018-10-23
MX2016014989A (es) 2017-03-31
PH12016502253A1 (en) 2017-01-16
AU2015261540A1 (en) 2017-01-12
SG11201609286VA (en) 2016-12-29
BR112016026787A2 (es) 2017-08-15
EP3143007A1 (en) 2017-03-22
CN106458931A (zh) 2017-02-22
IL248922A0 (en) 2017-01-31
KR20170005105A (ko) 2017-01-11
US9796686B2 (en) 2017-10-24
TW201625559A (zh) 2016-07-16

Similar Documents

Publication Publication Date Title
EP3621962A4 (en) ANTIBACTERIAL COMPOUNDS
SI3256138T1 (sl) Farmacevtski sestavki, ki obsegajo meloksikam
GEP20217239B (en) Pharmaceutical composition
EP3036639A4 (en) STORAGE CLUSTER
BR112016023628A2 (pt) composições farmacêuticas.
LT3177149T (lt) Bakterijų sporų kompozicijos, skirtos pramoniniam panaudojimui
EP3497210A4 (en) INNOVATIVE GLUCOSE OXIDASE COMPOSITIONS
EP3621961A4 (en) Antibacterial compounds
EP3102193A4 (en) Antibacterial agents: n(alpha)-aroyl-n-aryl-phenylalaninamides
EP3236978C0 (en) An antimicrobial composition
BR112016021012A2 (pt) composições farmacêuticas de compostos terapeuticamente ativos.
EP3126376C0 (en) POLYMYXIN DERIVATIVES USED AS ANTIMICROBIAL COMPOUNDS
FR3024465B1 (fr) Caracterisation de micro-organismes par maldi-tof
FI20165137A7 (fi) Ekspressiojärjestelmä eukaryoottisille mikro-organismeille
CL2016001349A1 (es) Uso de derivados de bencimidazol-prolina
EP3689849A4 (en) PERFUME PRECURSORS
GEP20217240B (en) Pharmaceutical composition
CL2015000430S1 (es) Alumbrado exterior.
BR112017013156A2 (pt) combinações de composto ativo.
LT3119198T (lt) Semiocheminės kompozicijos, skirtos sumažinti socialinį konfliktą tarp kačių
MX386975B (es) Fármacos precursores de oxabicicloheptanos.
ECSP17014972A (es) Compuestos de azetidiniloxifenilpirrolidina
BR112017013013A2 (pt) combinações de composto ativo
BR112017012801A2 (pt) combinações de composto ativo.
FR3020948B1 (fr) Composition antimicrobienne